Alto Neuroscience (ANRO) Liabilities and Shareholders Equity (2023 - 2026)

Alto Neuroscience has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $276.3 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $276.3 million, up 60.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $765.8 million (up 3.71% YoY), and the FY2025 annual result was $184.7 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity came in at $276.3 million for Q1 2026 at Alto Neuroscience, up from $184.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $276.3 million in Q1 2026 to a low of $86.6 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $181.1 million (2024), against an average of $180.1 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 104.95% in 2024 and declined 23.28% in 2025, its largest moves.
• Alto Neuroscience's Liabilities and Shareholders Equity stood at $86.6 million in 2023, then soared by 104.95% to $177.5 million in 2024, then increased by 4.03% to $184.7 million in 2025, then jumped by 49.58% to $276.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $276.3 million (Q1 2026), $184.7 million (Q4 2025), and $147.0 million (Q3 2025), per Business Quant data.